Autologous BMA vs Saline and LAM + LP-PRP vs Saline Evaluations in Knee OA
Recruiting now · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Osteoarthritis, Knee
In brief
ABLE OA is a Health Canada authorized (phase II/III) trial \[Parent Control #: 263591\]. A multi-center, prospective, double-blinded, randomized, placebo-controlled adaptive trial to evaluate the efficacy of two minimally manipulated autologous cellular preparations i) bone marrow aspirate (BMA) injection; and, ii) combined lipoaspirate micronized (LAM) and leukocyte poor (LP) platelet-rich plasma (PRP) injections for the treatment of knee osteoarthritis (OA). BMA, LAM from lipoaspirate (LA), and LP-PRP from whole blood will be prepared using the Cervos Marrow Cellution™ Bone Marrow Aspiration System, Cervos LIPO-PRO™ Adipose Transfer System, and Cervos KEYPRP Platelet Separator System, respectively. Patient-reported outcome (PRO) measures will be collected using web- or paper-based questionnaires administered at baseline (pre-injection) as well as at 3, 6 and 12 months (post-injection). Blood, synovial fluid, and urine samples will be collected at baseline pre-injection and 6 months post-injection only.
Key facts
- Study ID
- NCT05517434
- Run by
- University Health Network, Toronto
- People needed
- 148
- Starts
- 2025-01-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2025-12-19
Who can join
Age: 30 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female at least 30 years of age at the time of screening
- Willingness and ability to comply with study procedures and visit schedules and able to follow oral and written instructions
- Signed consent for study participation
- Baseline NPRS ≥ 4 points
- Presence of chronic, symptomatic knee pain in at least one knee; if both knees are affected, the knee with greater severity will be selected for treatment
- KL grade 2 or 3 knee OA based on standing knee X-ray assessment
- Body mass index ≤ 30 kg/m2
You may not qualify if…
- Approved anti-inflammatory therapy injections (corticosteroid, Synvisc, PRP, nSTRIDE-Autologous Protein Solution) within the previous 6 months in the knee
- Major axial deviation (varus >10°, valgus >10°)
- Any concomitant knee lesion causing pain or effusion (i.e., ligamentous or meniscal injury, osteochondral lesion)
- Presence of clinically observed active infection in the index knee
- Diagnosed with rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, or arthritis secondary to other inflammatory diseases; chondrocalcinosis, Paget's disease, or villonodular synovitis
- Diagnosed with leukemia or other hematologic cancers, known presence of metastatic malignant cells, or ongoing or planned chemotherapeutic treatment
- Presence of venous or lymphatic stasis in the index leg
- A history of local anesthetic allergy
- Medical conditions such as hemophilia or other blood clotting disorders
- Arthroscopic knee surgery within the previous 6 months
- Daily opioid use for the past 3 months, use of non-steroidal anti-inflammatory drugs within 1 week of the procedure, unable to hold anti-platelet medications
- Use of systemic corticosteroids for treatment of a chronic medical condition within the past 3 months
- Immunosuppression or acute infective processes
- Study Treatment Exclusion:
- For Study 1: Inability to tolerate the bone marrow aspiration procedure resulting in insufficient collection of BMA (<10 mL) after two successive aspiration attempts
- For Study 2: Inability to tolerate the lipoaspiration procedure resulting in insufficient collection of LA (<40 mL) after two successive aspiration attempts
Where it is running
- Toronto Western Hospital, University Health Network — Toronto, Ontario, Canada (enrolling)
- Women's College Hospital — Toronto, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.